SCHEMBL3858718

SCHEMBL3858718

N[C@@H](Cc1cn(Cc2ccc(Cl)cc2)c2ccccc12)C(=O)OCl

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
HTR6 P50406 1/20 0.52
YES1 P07947 2/20 0.50
KDR P35968 2/20 0.50
JAK3 P52333 2/20 0.50
CYP19A1 P11511 2/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPY1R P25929 1/20 0.48
HTT P42858 1/20 0.48
NPY2R P49146 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ADAM17 P78536 1/20 0.47
RECQL P46063 1/20 0.47
CNR2 P34972 1/20 0.47
NR4A1 P22736 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853915 0.90 KMT2A (0.57) KMT2AHTR6ALDH1A1LMNAMAPT
SCHEMBL3849188 0.87 CHRNB2 (0.58) KMT2AHTR6ALDH1A1LMNAMAPT
SCHEMBL3850017 0.86 HTR6 (0.55) KMT2AHTR6ALDH1A1MAPTADAM17
SCHEMBL3858228 0.85 KMT2A (0.48) KMT2AHTR6ALDH1A1MAPTADAM17
SCHEMBL3848100 0.83 ALDH1A1 (0.53) KMT2ACYP19A1ALDH1A1LMNAHTT
SCHEMBL3855610 0.83 KMT2A (0.55) KMT2AALDH1A1LMNAMAPTNPSR1
SCHEMBL3852360 0.83 KMT2A (0.52) KMT2ACYP19A1ALDH1A1LMNAMAPT
SCHEMBL3852576 0.82 RAB9A (0.55) KMT2ACYP19A1ALDH1A1MAPTKDM4E
SCHEMBL3854361 0.82 TP53 (0.52) KMT2AALDH1A1LMNAMAPTKDM4E
SCHEMBL9584105 0.82 KMT2A (0.65) KMT2AHTR6ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 KMT2A 1950/4885HTR6 299/4885YES1 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.